FDA Testimony Before the U.S. Senate Regarding Reauthorization of the Biosimilar User Fee Act
LexBlog IP
APRIL 29, 2022
Senate regarding reauthorization of the User Fee Acts, including the Biosimilar User Fee Act (“BsUFA”). The BsUFA is a law authorizing FDA to assess and collect fees from drug manufacturers that submit Biological License Applications for biosimilar products. decrease in price (for insulin glargine) to a 42.2%
52 
Let's personalize your content